---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-140321"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2021-11-17T23:59:59+00:00"
generated_at: "2026-06-28T07:15:56.372206+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Eloxx Phase 2 ELX-02 monotherapy shows 5.4 mmol/L sweat chloride reduction; advancing to Phase 3

## Summary
- Statistically significant 5.4 mmol/L mean sweat chloride reduction at 1.5 mg/kg/day (p=0.022) in Class 1 CF patients with G542X mutation.
- ELX-02 well tolerated; no treatment-related serious adverse events; most common mild injection site reactions.
- Planning for Phase 3 clinical development initiated; 1.5 mg/kg/day dose selected for further study.
- First patient dosed in Phase 2 combination arm with ivacaftor; topline data expected by H1 2022.
- Evaluation of inhaled delivery of ELX-02 started; IND submission planned for H2 2022.

## SEC filing metadata
- accession: 0001104659-21-140321
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2021-11-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465921140321/0001104659-21-140321-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465921140321/tm2133239d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-140321
- JSON: https://secwatch.observer/filing/0001104659-21-140321.json
- Plain text: https://secwatch.observer/filing/0001104659-21-140321.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.